Lack of pharmacokinetic interaction between vinpocetine and oxazepam. 1994

G Storm, and B Oosterhuis, and F A Sollie, and H W Visscher, and W Sommer, and H Beitinger, and J H Jonkman
Pharma Bio-Research International B.V., Zuidlaren, The Netherlands.

The influence of multiple doses of vinpocetine (10 mg three times daily) on the steady state plasma concentrations of oxazepam (10 mg three times daily) was studied in 16 healthy subjects. The mean (+/- s.d.) AUC (ng ml-1h-1) of oxazepam over 24 h during combined treatment was 4716 +/- 2296 and for oxazepam treatment alone it was 4737 +/- 2448 (95% confidence intervals for ratio of means = 95.4-103.7%). The degree of plasma protein binding of oxazepam was 98.11 +/- 0.32% and was not affected by vinpocetine. Independent of vinpocentine treatment a significant diurnal change in the plasma binding of oxazepam was observed; the free drug fraction was 20% higher during the night than during the day. Cmax and AUC values based on total oxazepam in plasma were 10% lower during the night. The results indicate a lack of influence of vinpocetine on oxazepam kinetics. Diurnal changes in the plasma binding of oxazepam probably have no clinical consequences.

UI MeSH Term Description Entries
D008297 Male Males
D010076 Oxazepam A benzodiazepine used in the treatment of anxiety, alcohol withdrawal, and insomnia. Adumbran,Serax,Tazepam
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D001798 Blood Proteins Proteins that are present in blood serum, including SERUM ALBUMIN; BLOOD COAGULATION FACTORS; and many other types of proteins. Blood Protein,Plasma Protein,Plasma Proteins,Serum Protein,Serum Proteins,Protein, Blood,Protein, Plasma,Protein, Serum,Proteins, Blood,Proteins, Plasma,Proteins, Serum
D002851 Chromatography, High Pressure Liquid Liquid chromatographic techniques which feature high inlet pressures, high sensitivity, and high speed. Chromatography, High Performance Liquid,Chromatography, High Speed Liquid,Chromatography, Liquid, High Pressure,HPLC,High Performance Liquid Chromatography,High-Performance Liquid Chromatography,UPLC,Ultra Performance Liquid Chromatography,Chromatography, High-Performance Liquid,High-Performance Liquid Chromatographies,Liquid Chromatography, High-Performance
D002940 Circadian Rhythm The regular recurrence, in cycles of about 24 hours, of biological processes or activities, such as sensitivity to drugs or environmental and physiological stimuli. Diurnal Rhythm,Nyctohemeral Rhythm,Twenty-Four Hour Rhythm,Nycthemeral Rhythm,Circadian Rhythms,Diurnal Rhythms,Nycthemeral Rhythms,Nyctohemeral Rhythms,Rhythm, Circadian,Rhythm, Diurnal,Rhythm, Nycthemeral,Rhythm, Nyctohemeral,Rhythm, Twenty-Four Hour,Rhythms, Circadian,Rhythms, Diurnal,Rhythms, Nycthemeral,Rhythms, Nyctohemeral,Rhythms, Twenty-Four Hour,Twenty Four Hour Rhythm,Twenty-Four Hour Rhythms
D004347 Drug Interactions The action of a drug that may affect the activity, metabolism, or toxicity of another drug. Drug Interaction,Interaction, Drug,Interactions, Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000704 Analysis of Variance A statistical technique that isolates and assesses the contributions of categorical independent variables to variation in the mean of a continuous dependent variable. ANOVA,Analysis, Variance,Variance Analysis,Analyses, Variance,Variance Analyses

Related Publications

G Storm, and B Oosterhuis, and F A Sollie, and H W Visscher, and W Sommer, and H Beitinger, and J H Jonkman
January 2000, Journal of clinical pharmacology,
G Storm, and B Oosterhuis, and F A Sollie, and H W Visscher, and W Sommer, and H Beitinger, and J H Jonkman
September 1985, Clinical pharmacology and therapeutics,
G Storm, and B Oosterhuis, and F A Sollie, and H W Visscher, and W Sommer, and H Beitinger, and J H Jonkman
February 1993, Therapeutic drug monitoring,
G Storm, and B Oosterhuis, and F A Sollie, and H W Visscher, and W Sommer, and H Beitinger, and J H Jonkman
July 1998, AIDS (London, England),
G Storm, and B Oosterhuis, and F A Sollie, and H W Visscher, and W Sommer, and H Beitinger, and J H Jonkman
November 1998, Journal of clinical pharmacology,
G Storm, and B Oosterhuis, and F A Sollie, and H W Visscher, and W Sommer, and H Beitinger, and J H Jonkman
October 1987, Journal of clinical psychopharmacology,
G Storm, and B Oosterhuis, and F A Sollie, and H W Visscher, and W Sommer, and H Beitinger, and J H Jonkman
February 1998, The Annals of pharmacotherapy,
G Storm, and B Oosterhuis, and F A Sollie, and H W Visscher, and W Sommer, and H Beitinger, and J H Jonkman
June 1995, American journal of therapeutics,
G Storm, and B Oosterhuis, and F A Sollie, and H W Visscher, and W Sommer, and H Beitinger, and J H Jonkman
December 2005, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology,
G Storm, and B Oosterhuis, and F A Sollie, and H W Visscher, and W Sommer, and H Beitinger, and J H Jonkman
May 1996, International journal of clinical pharmacology and therapeutics,
Copied contents to your clipboard!